Original news and analysis on international IP policy
Access to affordable and quality medicines for all is one of the major commitments of the World Health Organization, and its new medicines and health products strategic framework for the next 15 years calls for new research and development (R&D) models, including delinkage of the R&D costs from the price of products, and fair pricing.
On 9 May 2017, a five year court battle between publishers and universities finally came to an end when the Supreme Court of India dismissed an appeal by the Indian Reprographic Rights Organization (IRRO) challenging an earlier judgment of Delhi High Court that ruled course packs in India legal for educational purposes.
In a case that gained wide international attention, issues such as the cost of textbooks in India were raised, students agitated for fair access to educational materials, and the jurisprudence on copyright in India has taken a leap forward. In this guest blog, Anubha Sinha, Programme Officer on Openness and Access to Knowledge at the Centre for Internet and Society India, discusses the judgment in the case known as the ‘Delhi University photocopy’ case, and what it means for access to educational materials in India.
The World Intellectual Property Organization members this week have discussed the first draft of the budget of the organisation for the biennium 2018/2019. Questions have been asked about how WIPO is contributing to the United Nations Sustainable Development Goals, how much WIPO committees and external offices will cost, and how WIPO can help developing countries increase their IP development.
The European Patent Office is seeking a successor to President Benoît Battistelli, whose term ends in June 2018. Will a new chief and new Administrative Council (AC) chairman be able to resolve the never-ending turmoil between management and staff?
The finances of the World Intellectual Property Organization are healthy to say the least. The United Nations organisation, the only one able to feed its budget from user fees, shows a net result of over US$30 million. This week, WIPO member states are considering the budget for the 2018/2019 biennium, and as well which countries should be chosen to hold external WIPO offices.
The G20 governments against some odds passed a joint communique today, but had to accept differences on climate and in one point also on free trade. The US delegation remained firm in their decision to withdraw from the Paris climate agreement and continue to support conventional energy resources, instead of renewable ones. German Chancellor Angela Merkel in her press conference explained that there was a clear division in the climate chapter of the G20 2017 Declaration.
On the eve of the G20 meeting in Hamburg, Germany, German politicians described positions on free trade and climate as the most difficult issues. Expectations from civil society groups in the G20 results are modest at best and the 6 July protest march “Welcome to Hell” was cancelled after clashes between the police and parts of the protestors.
MONTREUX -- The legal profession is experiencing a “radical change” due to technology, a globally known author told the recent European IP Law Summit in Montreux, Switzerland. Technology has become “affordable” and professions “unaffordable” in a technology-based internet society, he said. Separately, a Belgian appeals court judge laid out details on the Unified Patent Court of Europe.
An African medicines agency, the continent’s first super-regulator, could be approved as soon as next year.
NAIROBI, Kenya - A generic version of dolutegravir (DTG), the drug of choice for the last two years for people living with HIV in high-income countries, is now available in Africa. On 28 June, the government of Kenya and drug pricing and innovation mechanism Unitaid unveiled the new first-line drug in an effort to accelerate access to better antiretroviral (ARV) drugs for her people living with HIV. It becomes the first country in Africa to introduce the generic version of drug.
In a decision today, the European Court of Justice in Luxembourg put an end to a complaint by Novartis Europharm Ltd against the European Commission over the terms for data exclusivity (C-629/15 P). Novartis had appealed an earlier decision by the European Court (the first instance) which had rejected the claims by the pharmaceutical company that it should be granted additional data exclusivity for Aclasta, developed from Novartis' older drug Zometa. No way, the Court of Justice said today, upholding the judgment by the lower court that had found that Novartis' interpretation of the rules would effectively allow the extension of data exclusivity for a drug forever.
European Patent Office employees, fed up with a series of reforms proposed by President Benoît Battistelli, have called “Respect Staff” strikes on 30 June and 3 July in all European Patent Office locations - Munich, The Hague, Berlin and Vienna.